Napp Pharmaceuticals Limited announced that Targinact, a fixed combination of prolonged-release oxycodone/naloxone, has received approval for use in the United Kingdom.

This follows the European Commission’s positive decision in January 2015 to recommend Targinact as a second line symptomatic treatment for patients with severe to very severe idiopathic restless legs syndrome (RLS), after failure of dopaminergic therapy.

Oxycodone/naloxone is the first opioid that has been granted a licence in the UK for the treatment of RLS. This new license indication provides a viable treatment option for patients who cannot tolerate the existing available treatments or who are not able to gain the level of symptom relief required.